Proton Pump Inhibitor Co-medication Reduces Mycophenolate Acid Drug Exposure in Heart Transplant Recipients

Journal of Heart and Lung Transplantation

Volumn 28, Issue 6, 2009, Pages 605-611

  Kofler, Sieglinde ^a   Deutsch, Marcus André ^a   Bigdeli, Amir K ^a   Shvets, Nataliya ^a   Vogeser, Michael ^b   Mueller, Thomas H ^b   Meiser, Bruno ^a   Steinbeck, Gerhard ^a   Reichart, Bruno ^a   Kaczmarek, Ingo ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DILTIAZEM; FUROSEMIDE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANTOPRAZOLE; PREDNISOLONE; SIMVASTATIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EXPOSURE; FEMALE; GRAFT RECIPIENT; HEART GRAFT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULAR DISEASE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL DISEASES; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROTON PUMP INHIBITORS; TACROLIMUS; TREATMENT OUTCOME;

EID: 65749114832     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.03.006     Document Type: Article

References (39)

1. Kobashigawa J.A., and Meiser B.M. Review of major clinical trials with mycophenolate mofetil in cardiac transplantation. Transplantation 80 suppl (2005) S235-S243
2. Keogh A. Long-term benefits of mycophenolate mofetil after heart transplantation. Transplantation 79 suppl (2005) S45-S46
3. Taylor D.O., Edwards L.B., Boucek M.M., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report-2007. J Heart Lung Transplant 26 (2007) 769-781
4. Staatz C.E., and Tett S.E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 46 (2007) 13-58
5. Shaw L.M., Korecka M., Venkataramanan R., et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 3 (2003) 534-542
6. Pou L., Branet M., Cantareel C., et al. Mycophenolic acid plasma concentrations: influence of comedication. Ther Drug Monit 23 (2001) 35-38
7. Diaz B., et al. Gastrointestinal complications in heart transplant patients: MITOS study. Transplant Proc 39 (2007) 2397-2400
8. Miura M., Armstrong V.W., et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit 30 (2008) 46-51
9. Shipkova M., Neidman P.D., Satoh S., Inoue K., et al. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem 44 (1998) 1481-1488
10. Rowland M.T.T. Clinical pharmacokinetics: concepts and applications (1989), Lea and Febiger, Philadelphia 459-63
11. Miura M., Inoue K., Kagaya H., et al. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharm Drug Dispos 28 (2007) 167-175
12. Homma M., Itagaki F., Yuzawa K., et al. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. Transplantation 73 (2002) 303-304
13. Kaczmarek I., Bigdeli A.K., Vogeser M., et al. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients. Ther Drug Monit 30 (2008) 419-427
14. Bullingham R., Shah J., Goldblum R., et al. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol 41 (1996) 513-516
15. Blume H., Donath F., Warnke A., et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Safety 29 (2006) 769-784
16. Huber R., Hartmann M., Bliesat H., et al. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 34 (1996) 185-194
17. Pue M.A., Laroche J., Meineke I., et al. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur J Clin Pharmacol 44 (1993) 575-578
18. Yacyshyn B.R., and Thomson A.B. The clinical importance of proton pump inhibitor pharmacokinetics. Digestion 66 (2002) 67-78
19. Bullingham R., Monroe S., Nicholls A., et al. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 36 (1996) 315-324
20. Bullingham R.E., Nicholls A., and Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 28 (1996) 925-929
21. Zwerner J., and Fiorentino D. Mycophenolate mofetil. Dermatol Ther 20 (2007) 229-238
22. West-Thielke P., and Kaplan B. Therapeutic monitoring of mycophenolic acid: is there clinical utility?. Am J Transplant 7 (2007) 2441-2442
23. del Mar Fernández De Gatta M., Santos-Buelga D., Domingues-Gil A., et al. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin Pharmacokinet 41 (2002) 115-135
24. Tomiyama Y., Morii M., and Takeguchi N. Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently. Biochem Pharmacol 48 (1994) 2049-2055
25. Tutuian R., Kalz P.O., Bochenek W., et al. Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers. Aliment Pharmacol Ther 16 (2002) 829-836
26. Somberg L., Morris Jr. J., Fantus R., et al. Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically III patients at risk of developing stress-related mucosal disease. J Trauma 64 (2008) 1202-1210
27. Pisupati J., Jain A., Burckart G., et al. Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol 45 (2005) 34-41
28. Tredger J.M., Brown N.W., Adams J., et al. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transplant 10 (2004) 492-502
29. van Gelder T., Le Meur Y., Shaw L.M., et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 28 (2006) 145-154
30. Weber L.T., Shipkova M., Armstrong V.W., et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German Study Group on Mycophenolate Mofetil Therapy. J Am Soc Nephrol 13 (2002) 759-768
31. Bullingham R.E., Nicholls A.J., and Kamm B.R. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34 (1998) 429-455
32. Kuypers D.R., Claes K., Evenepoel P., et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol 43 (2003) 866-880
33. Shaw L.M., Korecka M., Aradhye S., et al. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol 40 (2000) 624-633
34. Naesens M., Kuypers D.R., Streit F., et al. Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. Br J Clin Pharmacol 63 (2007) 541-547
35. Hunfeld N.G., Mathot R.A., Touw D.J., et al. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol 65 (2008) 752-760
36. Galiwango P.J., Delgado D.H., Yan R., et al. Mycophenolate mofetil dose reduction for gastrointestinal intolerance is associated with increased rates of rejection in heart transplant patients. J Heart Lung Transplant 27 (2008) 72-77
37. Kaczmarek I., Ertl B., Schmauss D., et al. Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil. J Heart Lung Transplant 5 (2006) 550-556
38. Meiser B.M., Pfeiffer M., Schmidt D., et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 18 (1999) 143-149
39. Eisen H.J., Kobashigawa J., Keogh A., et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 4 (2005) 17-25